Tests NX-1607 in adults with advanced cancers, first in people
Tests NX-1607, a new drug, in adults with advanced cancers for safety.
Key facts
- Who runs it
- Nurix Therapeutics, Inc.
- Where
- Cambridge, Glasgow, London, Manchester, Newcastle, Oxford, and Sutton, United KingdomSee the 7 sitesAlso in 1 other country, 10 sites
- Trial code
- Registry title
- A Study of NX-1607 in Adults With Advanced Malignancies
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 345 people, planned
- Started
- 29 Sept 2021
- Expected to end
- 28 Feb 2028
- Type of study
- Interventional, 12 groups
- Treatments tested
- NX-1607
- Paclitaxel
- Record updated
- 9 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced cancer that has spread or cannot be removed by surgery, who have already had standard treatment or cannot have it.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Metastatic or unresectable cancer with measurable disease, in one of these types: platinum-resistant ovarian, gastric/GEJ, head and neck squamous cell, melanoma, NSCLC, mCRPC, mesothelioma, triple negative breast, urothelial, cervical, MSS colorectal or DLBCL. ECOG performance status 0 or 1.
- Earlier treatment
- Must have had standard treatment options, or be unable to have them. Minimum 3 weeks or 5 half-lives (whichever is shorter) since the last systemic cancer therapy, and 2 weeks since the last radiotherapy.
Main reasons for not taking part
- Active untreated brain metastases
- Pregnant, breastfeeding, or planning to become pregnant
- Active autoimmune disease treated in the past 2 years, or history of uveitis
- Heart attack, unstable angina or serious heart failure within 6 months
- Active hepatitis A, B or C
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- Age ≥ 18 years
- Measurable disease per disease-specific response criteria
- Patients must have disease that is metastatic or unresectable and have received standard treatment options, are not candidates for standard treatment options, or will otherwise be prevented from receiving any standard treatment options
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Minimum of 3 weeks or 5 half-lives (whichever is shorter) since last dose of systemic cancer therapy (unless otherwise specified) or minimum of 2 weeks since last radiotherapy, or minimum of 6 weeks since last systemic therapy with nitrosoureas, antibody-drug conjugate, or radio immuno-conjugate therapy
- Adequate organ and bone marrow function, in the absence of growth factors (with limited exception for DLBCL), as defined by laboratory parameters
- Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol
- Patient must be willing and able to adhere to the prohibitions and restrictions specified in the protocol
- Each patient must sign an informed consent form (ICF)
- Histological or cytological diagnosis of platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma; gastric/GEJ cancer; HNSCC; recurrent and either metastatic or unresectable melanoma; NSCLC; mCRPC; MPM; TNBC; locally advanced or metastatic urothelial cancer; cervical cancer; MSS CRC; or DLBCL (including DLBCL-RT)
- Accessible tumor (for all cohorts) or lymph node (DLBCL only) for biopsy (Phase 1b only)
Who cannot take part
- History of CAR-T therapy within 30 days prior to the first dose of NX-1607
- Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for Grade 2 alopecia and Grade 2 peripheral neuropathy or patients receiving endocrine replacement therapy
- Patients who experienced Grade 3 or higher irAEs with prior immunotherapy
- Patient has had major surgery (e.g., requiring general anesthesia) within 4 weeks before the planned first dose of NX-1607, or will not have fully recovered from surgery, or has surgery planned during the time the patient is expected to participate in the study or within 4 weeks after the last dose of NX-1607. Note: Patients with minor planned surgical procedures to be conducted under local anesthesia may participate
- Vaccinated with a live vaccine within 28 days (with the exception of the annual inactivated influenza vaccine) or COVID-19 vaccination within 14 days prior to the first dose of NX-1607
- Current active hepatitis, including hepatitis A (hepatitis A virus immunoglobulin M [IgM] positive), hepatitis B (hepatitis B virus [HBV] surface antigen positive), or hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV RNA). Patients with HCV with undetectable virus after treatment are eligible. Patients with prior exposure to HBV may be entered if quantitative PCR is negative
- Use of systemic corticosteroids (> 20 mg prednisone or equivalent) within 15 days (except for prophylaxis for radio diagnostic contrast reactions and/or prophylaxis for patients receiving paclitaxel), or other immunosuppressive drugs within 30 days, prior to the first dose of NX-1607
- Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 µg [NIH 2020] (Note: Patients who switch from a high dose to a dose of 30 µg/day or less at least 1 day prior to Screening assessments are eligible for study entry)
- Receipt of an IP or has been treated with an investigational device within 3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of NX-1607
- Uncontrolled intercurrent illness including, but not limited to, poorly controlled hypertension or diabetes, or ongoing active infection requiring systemic therapy
- Psychiatric illness that would limit compliance with study requirements
- History of uveitis, or an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- Unable to swallow capsules or has malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction likely to interfere with the delivery, absorption, or metabolism of NX-1607
- Known allergies, hypersensitivity, or intolerance to components of NX-1607
- Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: Patients with well controlled HIV (e.g., CD4 > 350/mm3 and undetectable viral load) are eligible
- Treatment with any of the following prior to the first dose of NX-1607: CPI (anti-PD-1, PD-L1, cytotoxic T-lymphocyte-associated protein 4, etc) within 3 weeks; autologous or allogeneic stem cell transplant within 100 days; prior systemic cancer therapy within 3 weeks or 5 half-lives (whichever is shorter) (unless otherwise specified) (including hormonal therapy except for hormonal prophylaxis for a prior malignancy); prior radiotherapy within 2 weeks; prior systemic therapy with nitrosoureas, antibody-drug conjugate, or radio-immuno-conjugate therapy within 6 weeks; use of strong or moderate CYP3A4 inducers or inhibitors within 14 days or 7 days, respectively, or 5 half-lives (whichever is longer)
- Any of the following within 6 months prior to the first dose of NX-1607 or ongoing:; Myocardial infarction; Unstable angina; Unstable symptomatic ischemic heart disease; New York Heart Association Class III or IV heart failure; Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events); Any other significant cardiac condition (e.g., pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, or severe congenital heart disease); Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator in consultation with the Medical Monitor
- Active known second malignancy with the exception of any of the following:; Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer; Adequately treated Stage I cancer from which the patient is currently in remission and has been in remission for ≥ 2 years; Low-risk prostate cancer with Gleason score < 7 and PSA < 10 ng/mL; Any other cancer from which the patient has been disease-free for ≥ 2 years
- Active untreated brain metastases
- Patient has any of the following:
- Patients with primary refractory EOC defined as patients who do not respond to their first platinum-containing regimen or who relapse less than 6 months after completion of that first platinum-containing regimen
- Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of NX-1607
- Patient is a man who plans to father a child while enrolled in this study or within 3 months after the last dose of NX-1607 and, as applicable, within 6 months after the last dose of paclitaxel
Where in United Kingdom
Also in 1 other country, 10 sites
- Addenbrookes Cambridge University HospitalCambridge, United KingdomContact: Nurix Therapeutics Patient OutreachTaking people
- Beatson West of Scotland Cancer CentreGlasgow, United KingdomContact: Ruth OrrTaking people
- Sarah Cannon Research InstituteLondon, United KingdomContact: ReferralsTaking people
- The Christie NHS Foundation TrustManchester, United KingdomContact: The Christie EnquiriesTaking people
- Northern Centre for Cancer CareNewcastle, United KingdomContact: Nurix Therapeutics Patient OutreachTaking people
- Churchill HospitalOxford, United KingdomContact: Nurix Therapeutics Patient OutreachNo longer taking part
- Royal Marsden Hospital NHS Foundation TrustSutton, United KingdomContact: Nurix Therapeutics Patient OutreachTaking people
About the trial
What the trial wants to find out
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
The 12 groups in the trial
- Phase 1a Dose Escalation of NX-1607 (monotherapy)Treatment being tested
Multiple dose levels and dosing regimen of NX-1607 to be evaluated; determination of MTD/Phase 1b recommended dose.
Treatment: NX-1607
- Phase 1a Food EffectTreatment being tested
Impact of food on NX-1607 bioavailability and tolerability to be evaluated
Treatment: NX-1607
- Phase 1b Dose Expansion in platinum-resistant EOCTreatment being tested
Patients with platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma
Treatment: NX-1607
- Phase 1b Dose Expansion in advanced gastric/GEJ cancerTreatment being tested
Patients with recurrent, locally advanced, or metastatic gastric or GEJ adenocarcinoma
Treatment: NX-1607
- Phase 1b Dose Expansion in HNSCCTreatment being tested
Patients with recurrent, locally advanced, or metastatic HNSCC
Treatment: NX-1607
- Phase 1b Dose Expansion in recurrent melanomaTreatment being tested
Patients with recurrent and either metastatic or unresectable Melanoma
Treatment: NX-1607
- Phase 1b Dose Expansion in advanced NSCLCTreatment being tested
Patients with Stage IV NSCLC
Treatment: NX-1607
- Phase 1b Dose Expansion in mCRPCTreatment being tested
Patients with mCRPC who received a minimum of 2 prior lines of therapy in the advanced setting including androgen receptor-directed therapy and a taxane-based chemotherapy and has PSA or radiographic progression
Treatment: NX-1607
- Phase 1b Dose Expansion in mixed solid tumor cohortTreatment being tested
Cohort of mixed solid tumor indications consisting of patients with MPM, TNBC, locally advanced or metastatic urothelial cancer, cervical cancer, or DLBCL/DLBCL-RT
Treatment: NX-1607
- Phase 1a Dose Escalation of NX-1607 in combination with PaclitaxelTreatment being tested
Indications may include but are not limited to, platinum resistant EOC, gastric/GEJ cancer. HSNCC, NSCLC, TNBC, locally advanced or metastatic urothelial cancer and cervical cancer.
Treatment: NX-1607 and Paclitaxel
- Phase 1b Dose Expansion of NX-1607 in combination with PaclitaxelTreatment being tested
Indications may include but are not limited to, platinum resistant EOC, gastric/GEJ cancer, HSNCC, NSCLC, TNBC, and locally advanced or metastatic urothelial cancer and cervical cancer
Treatment: NX-1607 and Paclitaxel
- Phase 1b Dose Expansion in MSS CRCTreatment being tested
Patients with histologically confirmed MSS CRC, known KRAS WT, and must have been previously treated with \> = 2 lines of systemic therapy including a fluoropyrimidine, irinotecan, and/or oxaliplatin (and EGFR inhibitor if known Ras wild type)
Treatment: NX-1607
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
- Plain-language title
- Tests NX-1607 in adults with advanced cancers, first in peopleGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 September 2025